Alexion Will Face Securities Class Action Over Soliris Sales

Alexion Pharmaceuticals Inc. must face a securities class action related to the sales of its lone commercial drug and the suit will be championed by an investment company and retirement plan, a federal court said.

Alexion specializes in drugs used to treat illnesses that affect less than 200,000 people. Its drug, Soliris, is used to reduce symptoms of paroxysmal nocturnal hemoglobinuria, a blood disease, and atypical hemolytic uremic syndrome, a kidney disease.

The suit alleged that, between January 2014 and May 2017, Alexion’s growth of the Soliris market in other countries was obtained through illegal and unethical sales practices. It ...